Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP007: Comprehensive epigenome-wide DNA methylation profiling in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

N. Ventham*1, N. Kennedy1, A. Adams1, R. Kalla1, S. Heath2, K. O’Leary1, H. Drummond1, D. Wilson3, T. IBD-BIOM Consortium1, T. IBD-CHARACTER Consortium1, I. Gut2, E. R. Nimmo1, J. Satsangi1

1University of Edinburgh, CGEM, Edinburgh, United Kingdom, 2Centro Nacional de Análisis Genómico, Barcelona, Spain, 3University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom

OP008: Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitisECCO '16 Amsterdam
Year: 2016
Authors:

R. Alberts*1, E. M. de Vries2, G. Alexander3, D. Alvaro4, A. Bergquist5, U. Beuers2, E. Björnsson6, K. M. Boberg7, C. L. Bowlus8, R. W. Chapman9, O. Chazouillères10, A. Cheung11, G. Dalekos12, B. Eksteen13, D. Ellinghaus14, M. Färkkilä15, E. A. Festen1, A. Floreani16, T. Folseraas7, E. Goode17, D. N. Gotthardt18, G. M. Hirschfield19, B. van Hoek20, K. Holm7, S. Hohenester21, J. R. Hov7, F. Imhann1, P. Invernizzi22, X. Jiang7, J. Eaton23, B. D. Juran24, K. N. Lazaridis24, V. Leppa25, J. Z. Liu26, J. Löfberg27, M. P. Manns28, H.-U. Marschall29, M. Marzioni30, A. L. Mason31, E. Melum7, P. Milkiewicz32, T. Müller33, A. Pares34, C. Rupp35, S. M. Rushbrook36, C. Rust37, F. Sampaziotis38, R. N. Sandford39, C. Schramm40, S. Schreiber14, E. Schrumpf7, M. Silverberg41, B. Srivastava39, M. Sterneck42, A. Teufel43, L. Tittmann44, L. Vallier38, A. V. Vila1, B. de Vries1, T. J. Weismüller28, C. Wijmenga45, K. Zachou46, A. Franke14, C. A. Anderson47, T. H. Karlsen7, C. Y. Ponsioen2, R. K. Weersma1

1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 3University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, 4Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, 5Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, 6Landspitali University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, 7Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Centre, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, 8University of California Davis, Division of Gastroenterology and Hepatology, Davis, California, United States, 9John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, 10Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, 11University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, 12Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, 13University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, 14Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 15Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, 16University of Padova, Dept. of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, 17Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, 18University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, 19University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, 20Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 21University of Munich, Department of Medicine II, Munich, Germany, 22Humanitas Clinical and Research Centre, Centre for Autoimmune Liver Diseases, Rozzano, Italy, 23Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 24Mayo Clinic, College of Medicine, Centre for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 25Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, 26Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 27Karolinska Institute, Department of, Stockholm, Sweden, 28Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 29Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, 30Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, 31University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Alberta, Canada, 32Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, 33Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, 34University of Barcelona, Liver Unit, Hospital Clinic, I.D.I.B.A.P.S., C.I.B.E.R.ehd, Barcelona, Spain, 35University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, 36University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, 37University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, 38Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, 39University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, 40University Medical Centre Hamburg-Eppendorf, 1st Department of Medicine, Hamburg, Germany, 41Mount Sinai Hospital Toronto, Inflammatory Bowel Disease Group, Zane Cohen Centre for Digestive Diseases, Toronto, Ontario, Canada, 42University Medical Centre Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, 43University of Mainz, First Department of Medicine, Mainz, Germany, 44Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, 45University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 46University of Thessaly, Department of Internal Medicine, Larissa, Greece, 47Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, Massachusetts, United States

OP009: Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

F. Imhann*1, A. Vich Vila1, M. J. Bonder2, D. Gevers3, J. Fu2, M. C. Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R. W. F. Ter Steege1, C. Huttenhower4, G. Dijkstra1, R. J. Xavier3, C. Wijmenga2, E. A. M. Festen1, A. Zhernakova2, R. K. Weersma1

1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, 4Harvard School of Public Health, Biostatistics Department, Boston, Massachusetts, United States

OP010: Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective studyECCO '16 Amsterdam
Year: 2016
Authors:

E. Del Tedesco1, S. Paul2, H. Marotte3, C. Jarlot1, N. Williet4, J. M. Phelip4, L. Peyrin Biroulet5, J. F. Colombel6, X. Roblin*4

1University Hospital, Gastroenterology, Saint-Etienne, France, 2University of Saint-Etienne, Immunology, Saint-Etienne, France, 3University Hospital, Rheumatology, Saint-Etienne, France, 4CHU Saint-Etienne, Saint-Etienne, France, 5CHU de Nancy, Department of Gastroenterology, Vandoeuvre-lès-nancy, France, 6Mount Sinai Hospital, New York, New York, United States

OP011: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)ECCO '16 Amsterdam
Year: 2016
Authors:

T. Matsumoto*1, S. Motoya2, K. Watanabe3, T. Hisamatsu4, H. Nakase5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe11, T. Hibi17

1Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, 2Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan, 3Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, 4Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 5Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan, 6Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, 7Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 8Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, 9Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan, 10Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 11Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, 14Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 15Toho University Sakura Medical Centre, Department of Internal Medicine, Sakura, Japan, 16The Institute of Medical Science Hospital, The University of Tokyo, Centre for Translational Research, Tokyo, Japan, 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan

OP012: Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programmeECCO '16 Amsterdam
Year: 2016
Authors:

C. H. R. Choi*1, 2, I. Al Bakir1, 2, N. S. J. Ding1, M. Moorghen1, S. Thomas-Gibson1, J. Warusavitarne1, B. Saunders1, M. Rutter3, T. Graham2, A. Hart1

1St. Mark’s Hospital, London, United Kingdom, 2Barts Cancer Institute, Tumour Biology, London, United Kingdom, 3University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom

OP013: Evolution of corticosteroid use in Crohn’s disease patients between 1991 and 2014: results from the Dutch population-based Inflammatory Bowel Disease South Limburg cohortECCO '16 Amsterdam
Year: 2016
Authors:

S. Jeuring*1, 2, V. Biemans1, L. Liu1, T. Van den Heuvel1, 2, M. Zeegers3, 4, 
W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

1Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, 4Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, 5Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, 6Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

OP014: A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s disease refractory to anti-tumour necrosis factor α: UNITI-1ECCO '16 Amsterdam
Year: 2016
Authors:

P. Rutgeerts*1, C. Gasink2, M. Blank3, Y. Lang2, J. Johanns2, L.-L. Gao2, B. Sands4, S. Hanauer5, B. Feagan6, S. Targan7, S. Ghosh8, W. de Villiers9, J.-F. Colombel10, S. Lee11, P. Desreumaux12, E. V. Loftus, Jr13, S. Vermeire14, W. J. Sandborn15

1University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 2Janssen R & D, LLC, Spring House, United States, 3Janssen Scientific Affairs, LLC., Horsham, United States, 4Mount Sinai Medical Centre, New York, New York, United States, 5Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 6Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, 7Cedars-Sinai Medical Centre, Division of Gastroenterology, Los Angeles, California, United States, 8University of Calgary, Department of Gastroenterology, Calgary, Canada, 9Universiteit Stellenbosch University, Stellenbosch, South Africa, 10Mount Sinai, Icahn School of 
Medicine, New York, New York, United States, 11University of Washington, Seattle, Washington, United States, 12University of Lille, Lille, France, 13Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States, 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 15University of California San Diego, Division of Gastroenterology, La Jolla, California, United States

OP015: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn’s disease who are anti-tumour necrosis factor inadequate respondersECCO '16 Amsterdam
Year: 2016
Authors:

S. Danese*1, S. Vermeire2, P. Hellstern3, R. Panaccione4, G. Rogler5, G. Fraser6, A. Kohn7, P. Desreumaux8, R.W. Leong9, G.M. Comer10, F. Cataldi10, A. Banerjee10, M.K. Maguire11, C. Li10, N. Rath11, J. Beebe10, S. Schreiber12

1Humanitas University Clinical and Research Hospital, Rozzano, Milan, Italy, 2University Hospitals Leuven, Leuven, Belgium, 3Nature Coast Clinical Research, Inverness, Florida, United States, 4University of Calgary, Calgary, Canada, 5University of Zürich, Zürich, Switzerland, 6Rabin Medical Centre and University of Tel-Aviv, Petah Tikva, Israel, 7AO San Camillo Forlanini, Rome, Italy, 8University of Lille, Inserm U995, Lille, France, 9Concord Hospital, Sydney, New South Wales, Australia, 10Pfizer Inc, Cambridge, Massachusetts, United States, 11Pfizer Inc, Collegeville, Pennsylvania, United States, 12Christian-Albrechts University, Kiel, Germany

OP016: Development and validation of diagnostic criteria for IBD-unclassified (IBDU) in children: a multicentre longitudinal study from the paediatric IBD Porto Group of ESPGHANECCO '16 Amsterdam
Year: 2016
Authors:

L. Birimberg Schwartz1, D. Zucker2, A. Akriv2, C. Salvatore3, F. Cameron4, I. Lazowska5, L. Yianni6, P. Siba7, S. Kolacek8, C. Romano9, S. Buderus10, A. Pærregaard11, J. C. Escher12, D. Turner*13

1Shaare Zedek Medical Centre, Paediatrics, Jerusalem, Israel, 2The Hebrew University, Jerusalem, Israel, 3Sapienza University of Rome, Rome, Italy, 4Yorkhill Children’s Hospital, Glasgow, United Kingdom, 5Medical University of Warsaw, Warsaw, Poland, 6University Hospital Southampton, Hampshire, United Kingdom, 7University of Dundee, Scotland, United Kingdom, 8Zagreb University Medical School, Zagreb, Croatia, 9University of Messina, Messina, Italy, 10St Marien Hospital, Bonn, Germany, 11Hvidovre University Hospital, Copenhagen, Denmark, 12Erasmus Medical Centre, Holland, Netherlands, 13Shaare Zedek Medical Centre, Jerusalem, Israel

OP017: Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trialECCO '16 Amsterdam
Year: 2016
Authors:

S. Paramsothy*1, M. Kamm2, 3, A. Walsh4, J. van den Bogaerde5, D. Samuel6, R. Leong6, S. Connor7, W. Ng7, R. Paramsothy7, N. Kaakoush8, H. Mitchell8, W. Xuan9, E. Lin10, T. Borody10

1University of New South Wales, St Vincent’s Clinical School, Sydney, Australia, 2St Vincent’s Hospital, Melbourne, Australia, 3Imperial College London, London, United Kingdom, 4St Vincent’s Hospital, Sydney, Australia, 5Nambour General Hospital, Nambour, Australia, 6Bankstown-Lidcombe Hospital, Sydney, Australia, 7Liverpool Hopsital, Sydney, Australia, 8University of New South Wales, School of Biotechnology & Biomolecular Sciences, Sydney, Australia, 9Ingham Institute, Sydney, Australia, 10Centre for Digestive Diseases, Sydney, Australia

OP018: The impact of ‘Crohn’s Disease-TReatment-with-EATing’ diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolismECCO '16 Amsterdam
Year: 2016
Authors:

V. Svolos*1, R. Hansen2, K. Hughes1, U. Z. Ijaz3, C. Quince4, D. Gaya5, R. Russell2, K. Gerasimidis1

1Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, 2Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, 3School of Engineering, University of Glasgow, Glasgow, United Kingdom, 4Warwick Medical School, University of Warwick, Warwick, United Kingdom, 5Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom

OP019: Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trialsECCO '16 Amsterdam
Year: 2016
Authors:

W. J. Sandborn1, B. E. Sands2, G. D’Haens*3, S. Vermeire4, S. Schreiber5, S. Danese6, J. Panés7, B. G. Feagan8, W. Reinisch9, W. Niezychowski10, G. Friedman10, N. Lawendy10, D. Yu10, D. Woodworth10, A. Mukherjee11, P. Healey11, H. Zhang10, C. Su10

1Division of Gastroenterology, University of California, San Diego, California, United States, 2Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States, 3Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, 4Dept of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 5Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, 6IBD Centre, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, 7Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 8Robarts Research Institute, London, Ontario, Canada, 9McMaster University, Hamilton, Canada, 10Pfizer Inc, Collegeville, Pennsylvania, United States, 11Pfizer Inc, Groton, Connecticut, United States

OP020: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: interim analysis from the Phase 2 FITZROY studyECCO '16 Amsterdam
Year: 2016
Authors:

S. Vermeire*1, S. Schreiber2, R. Petryka3, T. Kuehbacher4, X. Hebuterne5, X. Roblin6, M. Klopocka7, E. Goldis8, M. Wisniewska-Jarosinska9, A. Baranovsky10, R. Sike11, C. Tasset12, A. Van der Aa12, P. Harrison12

1UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, 2University Medical Centre Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, 3Vivamed, Warsaw, Poland, 4Asklepios Hospital West Hamburg, Department of Internal Medicine, Gastroenterology, Hamburg, Germany, 5Archet 2 Hospital, Department of Gastroenterology, Nice, France, 6Saint Etienne Hospital, Department of Gastroenterology, Saint Priest en Jarez, France, 7University Hospital Nr. 2 im. Biziela, Department of Gastroenterology, Bydgoszcz, Poland, 8Policlinica Algomed, Department of Gastroenterology, Timisoara, Romania, 9Saint Family Hospital Medical Centre, Department of Gastroenterology and Endoscopy, Lodz, Poland, 10City Clinical Hospital #31, St Petersburg, Russian Federation, 11Szent Margit Hospital, Department of Internal Medicine and Gastroenterology III, Budapest, Hungary, 12Galapagos NV, Department of Development, Mechelen, Belgium

Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor, which has demonstrated high efficacy in patients with rheumatoid arthritis. This 20-week Phase 2 study was designed to evaluate the efficacy and safety of filgotinib in patients with active Crohn’s disease.

OP021: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trialECCO '16 Amsterdam
Year: 2016
Authors:

G. D’Haens*1, R. Pannaccione2, P. D. R. Higgins3, J.-F. Colombel3, B. G. Feagan4, M. Moscariello5, G. Chan5, P. Healey6, W. Niezychowski5, W. Wang5, A. Marren5, E. Maller5

1Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, 2University of Calgary, Calgary, Canada, 3University of Michigan, Ann Arbor, Michigan, United States, 4Robarts Research Institute, London, Ontario, Canada, 5Pfizer Inc, Collegeville, Pennsylvania, United States, 6Pfizer Inc, Groton, Connecticut, United States

OP022: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn’s disease: results of a Phase 2b randomised placebo-controlled trialECCO '16 Amsterdam
Year: 2016
Authors:

J. Panés*1, W. J. Sandborn2, S. Schreiber3, B. E. Sands4, S. Vermeire5, G. Chan6, M. Moscariello6, W. Wang6, W. Niezychowski6, A. Marren6, P. Healey7, E. Maller6

1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2Division of Gastroenterology, University of California, San Diego, United States, 3Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, 4Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, 5Dept of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 6Pfizer Inc, Collegeville, United States, 7Pfizer Inc, Groton, United States

OP023: Comparison between newly developed narrow band imaging and panchromoendoscopy for surveillance colonoscopy in patients with ulcerative colitis: a prospective multicentre randomised controlled trial, navigator studyECCO '16 Amsterdam
Year: 2016
Authors:

K. Watanabe*1, M. Nishishita2, F. Shimamoto3, T. Fukuchi4, M. Esaki5, Y. Okamoto5, Y. Maehata5, S. Oka6, S. Nishiyama6, S. Fujii7, F. Hirai8, T. Inoue9, N. Hida10, R. Nozaki11, T. Sakurai12, K. Takeuchi13, M. Saruta14, S. Saito15, Y. Saito16, N. Ohmiya17, H. Kashida12, S. Tanaka6, T. Matsui8, Y. Suzuki18, Y. Ajioka19, H. Tajiri20

1Osaka City General Hospital, Gastroenterology, Osaka, Japan, 2Nishishita Gastrointestinal Hospital, Osaka, Japan, 3Faculty of Human Culture and Science Prefectural University of Hiroshima, Hiroshima, Japan, 4Osakafu Saiseikai Nakatsu Hospital, Gastroenterology and Hepatology, Osaka, Japan, 5Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 6Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan, 7Kyoto Katsura Hospital, Digestive Disease Centre, Department of Gastroenterology, Kyoto, Japan, 8Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, 9Osaka Medical College, Second Department of Internal Medicine, Osaka, Japan, 10Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, 11Takano Hospital, Division of Gastroenterology, Coloproctology Centre, Kumamoto, Japan, 12Kinki University, Department of Gastroenterology, Osaka, Japan, 13Toho University Sakura Medical Centre, Department of Internal Medicin, Chiba, Japan, 14The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan, 15The Jikei University School of Medicine, Department of Endoscopy, Tokyo, Japan, 16National Cancer Centre Hospital, Endoscopy Division, Tokyo, Japan, 17School of Medicine, Fujita Health University, Department of Gastroenterology, Aichi, Japan, 18Toho University Sakura Medical Centre, Department of Internal Medicine, Chiba, Japan, 19Graduate School of Medical and Dental Sciences, Niigata University, Division of Molecular and Diagnostic Pathology, Niigata, Japan, 20The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Endoscopy, Tokyo, Japan

OP024: Mucosal healing and dysplasia surveillance in a large referral Centre cohort of patients with Crohn’s disease and ulcerative colitis treated with vedolizumabECCO '16 Amsterdam
Year: 2016
Authors:

M. Noman1, M. Ferrante1, R. Bisschops1, G. De Hertogh2, K. Van Den Broeck1, K. Rans1, P. Rutgeerts1, S. Vermeire1, G. Van Assche*1

1UZ Leuven, Gastroenterology, Leuven, Belgium, 2UZ Leuven, Campus Gasthuisberg, Pathology, Leuven, Belgium

OP025: Escalation of medical therapy decreases need for repeat dilatation in Crohn’s anastomatic stricturesECCO '16 Amsterdam
Year: 2016
Authors:

N. S. Ding*1, 2, W. Yip1, R. Choi1, B. Saunders3, S. Thomas-Gibson3, N. Arebi1, A. Humphries3, A. Hart1

1St Mark’s Hospital, IBD, London, United Kingdom, 2Imperial College London, Department of Surgery and Cancer, London, United Kingdom, 3St Mark’s Hospital, Wolfson Unit For Endoscopy, Department of Gastroenterology, Harrow, United Kingdom

OP026: The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn’s disease following surgical resection in 240 patientsECCO '16 Amsterdam
Year: 2016
Authors:

I. Arnott1, C. Mowat2, H. Ennis3, C. Keerie3, S. Lewis3, N. Kennedy4, A. Cahill5, A. Morris5, M. Dunlop6, S. Bloom7, J. Lindsay8, S. Subramanian9, J. Satsangi*4, TOPPIC Trial Study Group10

1NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, 2NHS Tayside, Gastroenterology, Dundee, United Kingdom, 3University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom, 4University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 5NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, 6University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, 7University College Hospital, Department of Gastroenterology, London, United Kingdom, 8Bart’s Health NHS Trust, Newham University Hospital, Department of Gastroenterology, London, United Kingdom, 9Royal Liverpool University Hospital, Gastroenterology, Liverpool, United Kingdom, 10Toppic Trial Study Group, UK, United Kingdom